These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24650313)

  • 1. Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.
    Bhatty S; Ali A; Shetty R; Sumption KF; Cowley MJ; Jovin IS
    Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):463-74. PubMed ID: 24650313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
    Muñiz-Lozano A; Rollini F; Franchi F; Angiolillo DJ
    Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):197-213. PubMed ID: 23818658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Tricoci P; Newby LK
    Cardiol Rev; 2008; 16(2):89-94. PubMed ID: 18281911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
    Steinhubl SR
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S12-9. PubMed ID: 17224886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
    Hostetter JC; Bhatt DL
    Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention?
    Lincoff AM
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1583-5. PubMed ID: 26493251
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ; Guzman LA; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
    Alagona P
    J Invasive Cardiol; 2010 Jan; 22(1):40-4. PubMed ID: 20048399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing acute coronary syndromes: decades of progress.
    Lincoff AM
    Cleve Clin J Med; 2014 Apr; 81(4):233-42. PubMed ID: 24692442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy in patients undergoing percutaneous coronary intervention: economic considerations.
    Weintraub WS; Mandel L; Weiss SA
    Pharmacoeconomics; 2013 Nov; 31(11):959-70. PubMed ID: 24022207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of platelet therapy.
    Fry JA; Grines CL
    Semin Interv Cardiol; 2000 Sep; 5(3):117-28. PubMed ID: 11054909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
    Thomas D; Giugliano RP
    J Cardiovasc Pharmacol; 2008 May; 51(5):425-33. PubMed ID: 18418272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures.
    Dangas G; Fuster V
    Rev Port Cardiol; 1999 Feb; 18 Suppl 1():I49-53. PubMed ID: 10191675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in antiplatelet therapy for ACS and PCI.
    Moliterno DJ
    J Interv Cardiol; 2008 Dec; 21 Suppl 1():S18-24. PubMed ID: 19090933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.